Citrin Cooperman Enhances Presence in Life Sciences with Browne Consulting Acquisition

Citrin Cooperman Expands Its Reach with Browne Consulting Acquisition

Citrin Cooperman Advisors LLC, recognized as a leading provider of tax and advisory services, has made a significant move by acquiring Browne Consulting Group LLC, a prominent advisory firm based in Boston. This acquisition, announced on February 10, 2026, not only boosts Citrin Cooperman's capabilities in the Life Sciences and Biotech sectors but also enhances its foothold in Boston.

A Strategic Acquisition

Browne Consulting, founded in 2016, specializes in offering accounting and advisory services catering to venture-backed life science companies. With a strong team of approximately 60 professionals, Browne's expertise in the intricate landscapes of the Life Sciences and Biotech industries will provide immense value to Citrin Cooperman's diverse clientele. This strategic acquisition fits seamlessly into Citrin Cooperman's growth model, where alignment with firms sharing similar cultural and operational philosophies is key.

Alan Badey, CEO of Citrin Cooperman Advisors LLC, expressed enthusiasm about the acquisition, stating, "We are thrilled to welcome Browne into the Citrin Cooperman family. Our organizations share a deep commitment to client service, collaborative culture, and a passion for delivering strategic, industry-specific insights. Browne's depth of expertise in Life Sciences and Biotech consulting will accelerate our growth in this high-impact sector. Together, we will deliver even greater value to our clients as they navigate the complexities of innovation, regulation, and growth in the life sciences ecosystem."

Warren Browne, the founder of Browne Consulting, echoed these sentiments, emphasizing the shared values and commitment to integrity, innovation, and client success between the two firms. He stated, "We couldn't be more excited to join forces with Citrin Cooperman. Our cultural synergies have been evident since our early discussions, and together, our combined resources will enable us to tackle our clients’ most complex challenges effectively."

Expert Insights and Collaborative Culture

Allan Koltin, the CEO of Koltin Consulting Group, who advised both parties on the transaction, praised the merger as a well-thought-out decision that respects the unique cultures of both firms. He remarked, "This deal not only makes strategic sense but enhances the unique cultural DNA of each firm. Their collective expertise in navigating life sciences opportunities will be a substantial offering for clients looking for trusted advisors in a rapidly evolving landscape."

The integration of Browne Consulting into Citrin Cooperman aims to create a powerful platform that will serve clients better through deeper strategic guidance and operational support, all while maintaining the high standards of integrity and service that both firms are known for.

The Bigger Picture

This acquisition is part of Citrin Cooperman's broader strategic vision to expand thoughtfully by aligning with firms that prioritize excellence in service and a client-first mentality. By integrating Browne Consulting's specialized knowledge, Citrin Cooperman is well-positioned to meet the growing demands of life sciences firms and support them as they scale.

Citrin Cooperman has consistently been recognized for its outstanding service to middle-market businesses and high-net-worth individuals. With over 3,600 professionals, the firm is one of the fastest-growing accounting and advisory services in the U.S., focused on positive impacts for its clients and communities.

By bringing together the robust capabilities of Browne Consulting, Citrin Cooperman is set to make significant strides in its service delivery, ensuring its clients in the Life Sciences and Biotech industries receive unparalleled support and expertise as they navigate their unique challenges in today's complex environment.

In conclusion, Citrin Cooperman's acquisition of Browne Consulting marks a significant milestone that not only enhances its service offerings but also strengthens its position in the life sciences sector, setting the stage for continued growth and excellence.